Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Study of Afuresertib in Solid Tumors and Hematologic Malignancies
NCT01531894Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of afuresertib in solid tumor, hematologic malignancy, sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
afuresertib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT01531894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531894.